bims-evecad Biomed News
on Extracellular vesicles and cardiovascular disease
Issue of 2026–05–03
seven papers selected by
Cliff Dominy



  1. J Cell Mol Med. 2026 May;30(9): e71148
      Adipose-derived extracellular vesicles (ADEVs) secreted by adipose tissue have gained increasing attention due to their regenerative and immunomodulatory properties in cardiovascular diseases. They carry proteins, lipids, and nucleic acids that mediate intercellular communication and influence cardiac pathophysiology. In atherosclerosis, ADEVs promote vascular regeneration, protect endothelial integrity, modulate macrophage polarization, foam cell formation, and regulate lipid homeostasis. In myocardial infarction, they limit apoptosis, reduce fibrosis, stimulate angiogenesis, and regulate inflammation through miRNA-dependent paracrine mechanisms. While preclinical studies support their therapeutic relevance, clinical translation remains at an early stage due to fragmented evidence and lack of standardization in isolation methods, dosing, and safety assessment. This review synthesizes current pathophysiological and translational evidence on the role of ADEVs in cardiovascular repair and provides a structured perspective to guide the development of ADEV-based therapies toward clinical application.
    Keywords:  adipose tissue; adipose‐derived extracellular vesicles; adipose‐derived stem cells; cardiovascular diseases; extracellular vesicles
    DOI:  https://doi.org/10.1111/jcmm.71148
  2. Adv Sci (Weinh). 2026 Apr 27. e75445
      Myocardial infarction (MI) represents a major public health challenge. Extracellular vesicles (EVs) hold considerable promise as therapeutics for cardiovascular disorders. However, the targeted delivery of them to the heart has received relatively limited research. Acute MI is often accompanied by severe inflammation. After MI, numbers of monocytes/macrophages are rapidly mobilized from the circulation and accumulate within the ischemic myocardial tissue. This recruitment is driven by the inflammatory homing signals emanating from the injured cardiac region. In this work, we develop a biomimetic nanovesicle by fusing membranes isolated from bone marrow mononuclear cells (Mon) with extracellular vesicles derived from healthy human plasma (M-hEV). This biomimetic delivery platform achieves site-specific accumulation at damaged vascular endothelial cells and cardiomyocytes by leveraging two key molecular recognition mechanisms: the monocyte chemoattractant protein-1 (MCP-1)/C-C chemokine receptor 2 (CCR2) and intercellular adhesion molecule-1 (ICAM-1)/CD11b axes. The results indicate that M-hEV can inhibit apoptosis of vascular endothelial cells and cardiomyocytes, promote angiogenesis and regulate macrophage polarization at the cellular and animal levels. Furthermore, M-hEV can home to the MI heart, reduce the infarct size, reduce the inflammation level, and improve cardiac function. This biomimetic system provides a novel approach to explore new targeted drugs for MI treatment.
    Keywords:  delivery system; extracellular vesicle; mononuclear cell membrane; myocardial infarction; targeted therapy
    DOI:  https://doi.org/10.1002/advs.75445
  3. Drug Des Devel Ther. 2026 ;20 590015
      Cardiovascular disease remains the leading cause of death worldwide, with current therapies facing limitations in efficacy and safety. Chinese Herbal Medicine-Derived Exosomes (CHM-Exos) are nano-sized membrane vesicles secreted by herbal cells, capable of cross-species delivery of bioactive substances. While plant-derived extracellular vesicles have been extensively reviewed, analyses specifically focused on CHM-Exos in cardiovascular contexts remain limited. This review systematically examines the bioengineering applications and therapeutic mechanisms of CHM-Exos in cardiovascular diseases, addressing a critical gap in translational literature. Mechanistically, CHM-Exos show potential to alleviate oxidative stress and modulate vascular cell function, though direct cardiovascular evidence remains preliminary. Key translational barriers-including standardization challenges, scalability constraints, and regulatory uncertainties-are critically discussed, alongside strategies to advance these promising nanocarriers toward clinical application.
    Keywords:  Chinese herbal medicine-derived exosomes; bioengineering; cardiovascular diseases; engineering modification; targeted delivery
    DOI:  https://doi.org/10.2147/DDDT.S590015
  4. Eur J Clin Invest. 2026 May;56(5): e70212
       BACKGROUND: Human amniotic membrane mesenchymal stem cells (hAMSCs) hold strong cardioprotective potential, yet their mechanisms of action remain largely elusive.
    METHODS AND RESULTS: C57BL/6 mice were subjected to cardiac ischemia/reperfusion (I/R) and received intravenous (IV) 2 × 105 hAMSCs at 2, 7 or 14 days post-reperfusion. Cardiac function and MIAT/miR-150/HOXA4 signalling were assessed. Mice treated 2 days post-I/R markedly improved LVEF and reduced myocardial necrosis and fibrosis by Day 21. Minimal hAMSC engraftment, evidenced by SSEA-4 immunostaining, suggests paracrine rather than direct cellular effects. Guided by GWAS implicating miRNAs in myocardial infarction, we identified miR-150 as a key effector, finding that hAMSC upregulated cardiac miR-150 and suppressed HOXA4, a profibrotic target in ischemic myocardium. In parallel, hAMSC treatment reduced cardiac MIAT, a lncRNA that sequesters miR-150, uncovering a mechanism of cardioprotection via MIAT downregulation post-reperfusion. Notably, CRISPR-Cas9 miR-150-silenced hAMSC exhibited severely impaired cardioprotective effects compared to wild-type cells, confirming the functional role of miR-150. miR-150 was identified as a key extracellular vesicle (EV) cargo released by hAMSC under hypoxic conditions, both in vitro and in hAMSC-injected I/R mice. Strickingly, administration of miR-150-enriched EVs to mice recapitulated the therapeutic benefits of hAMSC, underscoring miR-150-5p as central mediator of hAMSC-iduced cardioprotection.
    CONCLUSIONS: hAMSCs promote cardioprotection following I/R via the MIAT/miR-150-5p/HOXA4 axis, in which miR-150-5p plays a central role. These findings provide loss-of-function evidence about the therapeutic potential of hAMSC-derived EVs as a novel cell-free exosome-based strategy for the treatment of acute myocardial infarction.
    Keywords:  HOXA4; MIAT; acute myocardial infarction; cardioprotection; extracellular vesicles; human amniotic mesenchymal stem cells; ischemia/reperfusion; miR‐150‐5p
    DOI:  https://doi.org/10.1111/eci.70212
  5. JACC Basic Transl Sci. 2026 Apr 29. pii: S2452-302X(26)00073-2. [Epub ahead of print]11(6): 101555
      Targeted intra-atrial delivery of GMP-grade human cardiac extracellular vesicles (EVs) was evaluated for prevention of postoperative atrial fibrillation (AF). EVs were manufactured under serum-free, xenogen-free GMP-compatible conditions and tested in rat and porcine sterile pericarditis models. In rats, intra-atrial EV delivery resulted in selective atrial retention without systemic toxicity. In pigs, EV administration was technically feasible, well tolerated, and completely prevented spontaneous AF while significantly reducing inducible AF. EV therapy also attenuated atrial inflammation and fibrosis without adverse end-organ effects. These findings support localized cardiac EV therapy as a first-in-human-ready, disease-modifying biologic strategy for postoperative AF prevention.
    Keywords:  atrial fibrillation; biologic therapy; cardiac fibrosis; extracellular vesicles; inflammation; postoperative atrial fibrillation
    DOI:  https://doi.org/10.1016/j.jacbts.2026.101555
  6. Cells. 2026 Apr 08. pii: 656. [Epub ahead of print]15(8):
      Cardiac fibrosis is a pathology induced by various conditions, such as myocardial infarction, or certain cardiomyopathies, and represents one of the most prevalent cardiac abnormalities. This process, defined as the excessive accumulation of extracellular matrix within damaged cardiac tissue, leads to significant complications, including impaired systolic and diastolic function as well as arrhythmias. Conventional therapies focus primarily on slowing down the progression of fibrosis. Recently, there has been a growing research interest in therapies based on stem cells and their derivatives, which hold the potential to greater decrease formation and area of fibrosis. In this review, we aim to systematise the most recent data regarding the application of these approaches. We focus on describing the types of cells employed, methods of their implementation, and strategies for optimising these processes. Particular attention is given to exosomes due to the reports highlighting their use as innovative and potentially effective tools in the treatment of cardiac diseases.
    Keywords:  cardiac fibrosis; exosome; stem cell; stem cell derivatives
    DOI:  https://doi.org/10.3390/cells15080656
  7. Adv Sci (Weinh). 2026 Apr 28. e21032
      Human induced pluripotent stem cell-derived cardiomyocytes are valuable for studying cell-cell communication and synchronization, but remain immature and often lack robust electrical and mechanical coupling. To address this, we investigated gap junction-mediated communication and developed plasma membrane vesicles enriched in functional connexin hemichannels, termed Connectosomes, to enhance intercellular coupling. Connectosomes display properly oriented connexins and enrich the Cx43 expression at cell-cell borders between cardiomyocytes. Through mathematical modeling and experimental validation, we demonstrate that Connectosome incorporation reinforces endogenous gap junctions, promotes synchronous calcium transients, and improves spatial coordination of beating across networks. Mechanistic studies using engineered cell lines with tagged connexin-43 confirm that channel orientation and functionality are critical, supporting a model in which Connectosomes contribute to gap junction coupling. These results show that Connectosomes can synchronize the beating of immature cardiomyocytes by boosting electrochemical communication, laying the groundwork for future therapeutic advances.
    Keywords:  biovesicles; cardiomyocytes; hiPSCs; synchronization
    DOI:  https://doi.org/10.1002/advs.202521032